FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVIB A	PPROVAL
OMB Number:	3235-028

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* $\underline{Hoerter\ Steven\ L.}$				2. Issuer Name and Ticker or Trading Symbol Deciphera Pharmaceuticals, Inc. [DCPH]						(Che	5. Relationship of Reporting (Check all applicable) X Director			on(s) to Issu 10% Ow			
(Last) (First) (Middle) C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET					3. Date of Earliest Transaction (Month/Day/Year) 02/18/2020						7	X Officer (give title below) Other (specify below) President and CEO				pecify	
(Street) WALTH			02451 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line) 【 Form fil	or Joint/Group Filing (Check Applicable rm filed by One Reporting Person rm filed by More than One Reporting rson					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				action 2A. Deemed Execution Date if any (Month/Day/Yea		Code (Instr. ar)		str. 3, 4 and 5	4 and 5) Securities Beneficiall Owned Fol Reported		Form:	Direct I Indirect E str. 4)	'. Nature of ndirect Beneficial Ownership Instr. 4)				
							Code	v	Amount	(A) o (D)	Price	Transacti (Instr. 3 a					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, Iran urity or Exercise (Month/Day/Year) if any Cod		Code (saction Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year) U		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	e s lly	Ownership Form: B Direct (D) O	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	un(s)		
Stock Option (Right to Buy)	\$54.87	02/18/2020		A		180,000		(1)		02/17/2030	Common Stock	180,000	\$0.00	180,00	00	D	

Explanation of Responses:

1. This stock option award was issued pursuant to Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments over a 4-year period following the vesting commencement date of 2/18/2020, subject to continued service through such dates.

Remarks:

/s/ Thomas Kelly, Attorney-in-02/20/2020 **Fact**

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.